Abstract
The endocannabinoid system is a physiological system, which is responsible for the control of glucose and lipid-metabolism, as well as for the regulation of the body weight. The endocannabinoid receptors are distributed both in the central and peripher nervous system. Different studies provide evidence that an hyperactive endocannabinoid system is involved in the development of different cardiovascular risk factors. The pharmacological blockade of these cannabinoid receptors may represent a new approach for cardiometabolic risk management.
MeSH terms
-
Blood Glucose / metabolism*
-
Body Weight / physiology*
-
Cannabinoid Receptor Modulators / physiology*
-
Controlled Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy
-
Endocannabinoids*
-
Energy Metabolism / drug effects
-
Energy Metabolism / physiology*
-
Europe
-
Humans
-
Insulin Resistance / physiology
-
Lipids / blood*
-
Obesity / drug therapy
-
Obesity / physiopathology
-
Overweight / drug therapy
-
Overweight / physiopathology
-
Piperidines / adverse effects
-
Piperidines / therapeutic use
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB1 / physiology
-
Rimonabant
Substances
-
Blood Glucose
-
Cannabinoid Receptor Modulators
-
Endocannabinoids
-
Lipids
-
Piperidines
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Rimonabant